| Literature DB >> 29720131 |
Francesco Strati1,2,3, Antonio Calabrò4, Claudio Donati1, Claudio De Felice5, Joussef Hayek6, Olivier Jousson2, Silvia Leoncini6, Daniela Renzi4, Lisa Rizzetto7, Carlotta De Filippo8, Duccio Cavalieri9.
Abstract
BACKGROUND: Rett syndrome (RTT) is a neurological disorder mainly caused by mutations in MeCP2 gene. It has been shown that MeCP2 impairments can lead to cytokine dysregulation due to MeCP2 regulatory role in T-helper and T-reg mediated responses, thus contributing to the pro-inflammatory status associated with RTT. Furthermore, RTT subjects suffer from an intestinal dysbiosis characterized by an abnormal expansion of the Candida population, a known factor responsible for the hyper-activation of pro-inflammatory immune responses. Therefore, we asked whether the intestinal fungal population of RTT subjects might contribute the sub-inflammatory status triggered by MeCP2 deficiency.Entities:
Keywords: Candida parapsilosis; Dysbiosis; Rett syndrome
Mesh:
Substances:
Year: 2018 PMID: 29720131 PMCID: PMC5930502 DOI: 10.1186/s12876-018-0785-z
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1a) Fluconazole and b) itraconazole resistance as measured by MIC values in C. albicans and C. parapsilosis isolates from HC and RTT subjects. MIC values are reported as means ± standard errors. Exact p-values are reported and considered significant if < 0.05
Antifungals resistance of Candida isolates from HC or RTT patients
| Species | Antifungals | Healthy controls (HC) | Rett syndrome (RTT) subjects | ||||||
|---|---|---|---|---|---|---|---|---|---|
| MIC (μg/ml) | aCBPs | MIC (μg/ml) | aCBPs | ||||||
| MIC50 | MIC90 | %S | %R | MIC50 | MIC90 | %S | %R | ||
|
| Fluconazole | 0.5 | > 64 | 75.6 | 24.4 | 1 | 2 | 75 | 25 |
| Itraconazole | 0.25 | > 8 | 36.6 | 63.4 | 0.0156 | 0.0156 | 100 | 0 | |
| 5-Flucytosine | 0.125 | 0.5 | 97.6 | 2.4 | 0.125 | 0.125 | 100 | 0 | |
|
| Fluconazole | 0.5 | 2 | 92.9 | 7.1 | 2 | > 64 | 64.3 | 35.7 |
| Itraconazole | 0.0156 | 0.125 | 100 | 0 | 0.0156 | > 8 | 64.3 | 35.7 | |
| 5-Flucytosine | 0.125 | 0.5 | 100 | 0 | 0.125 | 0.125 | 100 | 0 | |
|
b
| Fluconazole | 0.125 | 0.25 | 100 | 0 | > 64 | > 64 | 0 | 100 |
| Itraconazole | 0.0156 | 0.0156 | 100 | 0 | 8 | 8 | 0 | 100 | |
| 5-Flucytosine | 0.125 | 0.125 | 100 | 0 | 0.125 | 0.125 | 100 | 0 | |
aAccording to EUCAST recommendations; S sensible; R Resistant; MIC ranges: Fluconazole 0.125–64 μg/ml; Itraconazole 0.0156–8 μg/ml; 5-Flucytosine 0.125–64 μg/ml. bCandida spp. isolated from RTT subjects (i.e. C. glabrata, C. pararugosa and C. tropicalis); Candida spp. isolated from HC (i.e. C. deformans, C. intermedia and C. lusitaniae)
Fig. 2Multidimensional scaling analysis of C. parapsilosis genetic diversity calculated by UPGMA hierarchical clustering analysis of samples’ distance similarities (Jaccard index) from RAPD genotyping. C. parapsilosis isolates from HC and RTT subjects in green and red, respectively
Fig. 3Cytokines production by peripheral blood mononuclear cells (PBMCs; 5 × 105 cell) after stimulation with 5 × 106 heat-killed C. albicans or C. parapsilosis isolates from HC and RTT subjects. In panels a-d) are reported the values for the cytokines produced by innate immune cells (IL-1β, IL-6, TNFα and IL-10 after 24 h of PBMCs stimulation) while in e-h) the values for the cytokines produced following adaptive immune responses (IL-17A, IL-22, IFNγ and IL-10 after 5 days of PBMCs stimulation). The dots represent each of the three replicates per isolate tested; *p < 0.05, Wilcoxon rank-sum test